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METHODS 
Patients and controls. 
Patients with defined severe immunosuppression or HIV positivity, as well as patients with 
tuberculosis, obstructive pneumonia caused by neoplasia or pneumonia as terminal event of 
chronic and progressive disease, were excluded from the study. 
The pneumonia severity index (PSI) was measured using the Fine scale [17]. Acute 
respiratory distress syndrome (ARDS) was defined using the American European Consensus 
Conference Definition [18]. Multi-organ dysfunction syndrome (MODS) was defined using 
the American College of Chest Physicians/Society of Critical Care Medicine criteria [19]. A 
diagnosis of pneumococcal pneumonia was considered with one of the following criteria: 1) 
at least one blood, pleural fluid, or transthoracic needle aspiration culture positive for 
S.pneumoniae; 2) bacterial growth of ≥103 colony-forming units/milliliter (CFU/mL) of 
S.pneumoniae from a protected specimen brush, and/or ≥104 CFU/mL in bronchoalveolar 
lavage; 3) positive urinary antigen for S.pneumoniae with a diagnosis of probable 
pneumococcal pneumonia, using a commercially available immunochromatographic assay 
(Binax NOW). 
 
Statistical analysis 
The comparison of the distribution of genotypes based on the susceptibility, severity and 
outcome were performed with the χ2 test or Fisher exact test when needed, and odds ratios 
(OR) with 95% of confidence intervals (95% CI) were calculated.  The relation between 
severity or outcome and genotypes was evaluated by binary logistic regression models, and 
age, gender, hospital of origin and co-morbidities, or PSI and pathogen were included as 
independent variables. Survival rates were estimated using the Kaplan-Meier method and 
their comparison related to genotypes was performed with log-rank test. Multivariate 
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analysis adjusted for the independent variables was carried out with Cox proportional hazard 
model. Alleles and haplotypes were recoded in binary variables for dominant and recessive 
effects. Quantitative variables are presented using arithmetic mean ± SEM. The differences 
in serum levels with regard to the analyzed genotypes were compared with the U of Mann-
Whitney, or with the H of Kruskal-Wallis when more than two genotypes were present. 
Statistical significance was taken as P value < 0.05. Bonferroni correction for multiple 
comparisons was applied when the frequencies of SNPs and haplotypes were compared 
between patients and controls.  
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 TABLES 
 
Table E1. Resulting haplotypes from SNPs 
combination in SFTPA1 and SFTPA2 genes.  
Haplotype Nucleotide/amino acid 
SFTPA1 aa19 aa50 aa62* aa133* aa219 
6A C/Ala C/Leu G G C/Arg 
6A2 T/Val G/Val A A C/Arg 
6A3 T/Val C/Leu A A C/Arg 
6A4 T/Val C/Leu G A T/Trp 
      
SFTPA2 aa9 aa91 aa140* aa223  
1A C/Thr C/Pro C C/Gln  
1A0 A/Asn G/Ala C C/Gln  
1A1 C/Thr G/Ala T A/Lys  
1A2 C/Thr G/Ala C C/Gln  
1A3 A/Asn G/Ala T A/Lys  
1A5 C/Thr C/Pro T C/Gln  
 
SNPs: Single nucleotide polymorphisms. 
Haplotypes are named as 6An for SFTPA1 and 1An for 
SFTPA2 based on previous nomenclature [15]. Only those 
haplotypes with a frequency higher than 1% are depicted. 
*Nucleotide change that does not produce amino acid 
change. 
Garcia-Laorden et al 
 
5 
Table E2. Demographic and clinical 
characteristics of CAP patients. 
Characteristics* N (%) 
Age (682) 62.95 ± 17.73† 
Sex (682)  
     Male 435 (63.78) 
     Female 247 (36.22) 
ICU admission (682)  
     No (91.57±34.45  )‡ 526 (77.13) 
     Yes (118.41±40.29  ) ‡ 156 (22.87) 
MODS (682)  
     No (92.59±34.33) ‡ 593 (86.95) 
     Yes (133.68±39.86) ‡ 89 (13.05) 
ARDS (682)  
     No (96.67±37.23) ‡ 656 (96.19) 
     Yes (122.48±37.67) ‡ 26 (3.81) 
90-day exitus (682)  
     No (95.03±36.44) ‡ 636 (93.26) 
     Yes (134.67±33.60) ‡ 46 (6.74) 
28-day exitus (682)  
     No (95.70±36.66) ‡ 648 (95.01) 
     Yes (136.71±34.16) ‡ 34 (4.99) 
Co-morbidity (670)§  
     No 226 (33.14) 
     COPD 201 (30.00) 
     Asthma 29 (4.33) 
     Neoplasy 76 (11.34) 
     Ischemic cardiopathy 87 (12.99) 
     Diabetes 148 (22.09) 
     Renal insufficiency 50 (7.46) 
     Hepatic insufficiency 45 (6.72) 
     Neurological pathology 90 (13.43) 
     Autoimmune pathology 13 (1.94) 
     Psiquiatric pathology 5 (0.75) 
Pneumonia severity index (667)  
     I-III (low) 290 (43.48) 
     IV-V (moderate-high) 377 (56.52) 
Etiological agent identified (682)  
     No 408 (59.82) 
     Yes 274 (40.18) 
         Streptococcus pneumonia 163 (23.90) 
         Pseudomonas aeruginosa 19 (2.79) 
         Legionella ssp 13 (1.91) 
         Haemophylus influenza 9 (1.32) 
         Virus 11 (1.61) 
         Others 59 (8.65) 
 
CAP: Community-acquired pneumonia; ICU: 
Intensive care unit; MODS: Multi-organ dysfunction 
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syndrome; ARDS: Acute respiratory distress 
syndrome; COPD: Chronic obstructive pulmonary 
disease. 
*In brackets the number of patients with available data.  
†For age the value is mean ± standard deviation.  
‡Pneumonia Severity Index (mean ± SD). 
§Some patients had more than one co-morbidity.
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Table E3. Pairwise linkage disequilibrium measure (D’) for surfactant proteins 
A1, A2 and D alleles from 748 healthy controls.  
 
 SFTPA1*  
 
 6A 6A2 6A3 6A4 6A5 6A12 6A15 SP-D 
SF
TP
A2
*
 
1A 0.34 (<0.0001) 
0.72 
(<0.0001) - - 
1 
(<0.0001) - 
0.65 
(<0.0001) 
0.31 
(<0.0001) 
1A0 0.74 (<0.0001) 
0.40 
(<0.0001) 
0.40 
(<0.0001) 
0.61 
(<0.0001) - - - - 
1A1 - 0.50 (<0.0001) 
0.51 
(<0.0001) - - - - - 
1A2 - 0.48 (<0.0001) - 
0.37 
(<0.0001) - - - - 
1A3 - - - - - - - - 
1A7 - - - - - - - - 
1A10 - - - - - - - - 
1A13 - - - - - - - - 
 SP-D 0.93 (<0.0001) - - - - 
0.84 
(0.006) 
0.71 
(0.038)  
 
The numbers are D’ (P value). Those D’ values lower than 0.3, or with a corresponding 
P value higher than 0.05 have not been considered. 
*Haplotypes for SFTPA1 and SFTPA2, resulting from the different combinations of the three 
SNPs (Single nucleotide polymorphisms) studied at each gene, are denoted using the 
conventional nomenclature [15].  
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Table E4. Comparison of haplotypes of SFTPA1, 
SFTPA2 and SFTPD between patients with 
pneumococcal CAP and controls. 
Haplotype* Controls N=1538 
PCAP     
N=326 
P† 
OR (95%CI) 
SFTPA1    
   6A2 (TGC) 934 (60.7) 177 (54.3) 0.032 0.77 (0.60-0.99) 
SFTPA2    
   1A0 (AGC) 911 (59.2) 169 (51.8) 0.014 0.74 (0.58-0.95) 
   1A10 (CCA) 4 (0.3) 5 (1.5) 0.011
‡
 
5.97 (1.28-30.23) 
SFTPA1-SFTP2    
   6A2-1A0 802 (52.1) 147 (45.1) 0.022 0.75 (0.59-0.96) 
SFTPC-
SFTPA1-SFTP2    
   C-6A3-1A 3 (0.2) 4 (1.2) 0.021
‡
 
6.36 (1.07-43.53) 
 
Frequency values are the number of chromosomes (%). 
PCAP: Pneumococcal community-acquired pneumonia. 
Only those haplotypes with significant differences between 
PCAP and healthy controls were included. 
*Haplotypes for SFTPA1 and SFTPA2, resulting from the 
different combinations of the three SNPs (Single 
nucleotide polymorphisms) studied at each gene, are 
denoted using the conventional nomenclature [15].  
†P value for the bivariate comparison. 
‡P value by Fischer exact test. 
